Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06551142 · ClinicalTrials.gov registry record · Phase 1

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

A Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 1
Development phase
590
Enrollment target
20
Study locations

NCT06551142 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 590 participants, below the 1,618-participant average among 158 other Neoplasms trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06551142, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 1
Development phase
590 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.

Conditions Studied

Neoplasms

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Carboplatin
  • BIOLOGICAL Atezolizumab
  • DRUG Cisplatin
  • BIOLOGICAL GSK5764227

Study Locations (20)

Texas

  • GSK Investigational Site - Austin
  • GSK Investigational Site - Dallas
  • GSK Investigational Site - San Antonio
  • GSK Investigational Site - Tyler

Other

  • GSK Investigational Site - Rosario
  • GSK Investigational Site - Viedma

Ontario

  • GSK Investigational Site - Ottawa
  • GSK Investigational Site - Toronto

Quebec

  • GSK Investigational Site - Montreal
  • GSK Investigational Site - Sherbrooke

California

  • GSK Investigational Site - Stanford

Colorado

  • GSK Investigational Site - Denver

Connecticut

  • GSK Investigational Site - New Haven

Massachusetts

  • GSK Investigational Site - Boston

Trial Details

FieldValue
Enrollment Target 590 participants
Start Date 2024-09-30
Est. Completion 2027-05-19
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06551142

The ClinicalTrials.gov registry entry for NCT06551142 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,618-participant average among 158 other Neoplasms trials with a reported enrollment target (64% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT06551142 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Other, Ontario.

Frequently Asked Questions

What is clinical trial NCT06551142 about?

NCT06551142 is a clinical study titled "A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)". The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, c...

What is the current status of trial NCT06551142?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 590 participants. The study started on 2024-09-30. Estimated completion is 2027-05-19.

What conditions does trial NCT06551142 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT06551142?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Atezolizumab (BIOLOGICAL), Cisplatin (DRUG), GSK5764227 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06551142?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06551142 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.